Literature DB >> 24560884

Controlled nail delivery of a novel lipophilic antifungal agent using various modern drug carrier systems as well as in vitro and ex vivo model systems.

Sandy Naumann1, Jean-Philippe Meyer2, Andreas Kiesow3, Yahya Mrestani4, Johannes Wohlrab5, Reinhard H H Neubert6.   

Abstract

The penetration behavior into human nails and animal hoof membranes of a novel antifungal agent (EV-086K) for the treatment of onychomycosis was investigated in this study. The new drug provides a high lipophilicity which is adverse for penetration into nails. Therefore, four different formulations were developed, with particular focus on a colloidal carrier system (CCS) due to its penetration enhancing properties. On the one hand, ex vivo penetration experiments on human nails were performed. Afterwards the human nail plates were cut by cryomicrotome in order to quantify the drug concentration in the dorsal, intermediate and ventral nail layer using high-performance liquid chromatography (HPLC) with UV detection. On the other hand, equine and bovine hoof membranes were used to determine the in vitro penetration of the drug into the acceptor compartment of an online diffusion cell coupled with Fourier transform infrared attenuated total reflectance (FTIR-ATR) spectroscopy. In combination, both results should exhibit a correlation between the EV-086K penetration behavior in human nail plates and animal hoof membranes. The investigations showed that the developed CCS could increase drug delivery through the human nail most compared to other formulations (nail lacquer, solution and hydrogel). Using animal hooves in the online diffusion cell, we were able to calculate pharmacokinetic data of the penetration process, especially diffusion and permeability coefficients. Finally, a qualitative correlation between the penetration results of human nails and equine hooves was established.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antifungal; Colloidal drug carrier system; FTIR-ATR spectroscopy; Human nail; Model membranes; Nail penetration

Mesh:

Substances:

Year:  2014        PMID: 24560884     DOI: 10.1016/j.jconrel.2014.02.013

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  7 in total

Review 1.  Transungual permeation: current insights.

Authors:  Ronak S Bhuptani; Ketaki M Deshpande; Vandana B Patravale
Journal:  Drug Deliv Transl Res       Date:  2016-08       Impact factor: 4.617

Review 2.  Mechanistic Insights of Formulation Approaches for the Treatment of Nail Infection: Conventional and Novel Drug Delivery Approaches.

Authors:  Agrawal Vikas; Patel Rashmin; Patel Mrunali; Rahul B Chavan; Thanki Kaushik
Journal:  AAPS PharmSciTech       Date:  2020-01-14       Impact factor: 3.246

3.  Poly(pseudo)rotaxanes formed by mixed micelles and α-cyclodextrin enhance terbinafine nail permeation to deeper layers.

Authors:  Anna Paula Krawczyk-Santos; Ricardo Neves Marreto; Angel Concheiro; Carmen Alvarez-Lorenzo; Stephânia Fleury Taveira
Journal:  Int J Pharm X       Date:  2022-05-10

4.  Preparation and in vivo evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis.

Authors:  Byung Chul Lee; Rudra Pangeni; Jungtae Na; Kyo-Tan Koo; Jin Woo Park
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

5.  Recent Patents on Permeation Enhancers for Drug Delivery Through Nails.

Authors:  Tainá Kreutz; Sheila Porto de Matos; Letícia Scherer Koester
Journal:  Recent Pat Drug Deliv Formul       Date:  2019

Review 6.  Onychomycosis: Potential of Nail Lacquers in Transungual Delivery of Antifungals.

Authors:  Nida Akhtar; Hemlata Sharma; Kamla Pathak
Journal:  Scientifica (Cairo)       Date:  2016-03-30

7.  Improving Transungual Permeation Study Design by Increased Bovine Hoof Membrane Thickness and Subsequent Infection.

Authors:  Sebastian Kappes; Thilo Faber; Lotta Nelleßen; Tanju Yesilkaya; Udo Bock; Alf Lamprecht
Journal:  Pharmaceutics       Date:  2021-12-06       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.